Detalhe da pesquisa
1.
Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR).
Oncologist
; 26(7): 560-e1103, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33829609
2.
An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.
Oncologist
; 24(2): 202-210, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30190302
3.
Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.
Oncologist
; 24(11): 1497-1501, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31399500
4.
Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial.
J Med Internet Res
; 21(5): e12044, 2019 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31045501
5.
A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.
Cancer
; 122(15): 2389-98, 2016 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27198170
6.
The Role of Nurses in the Management of Adverse Events in Patients Receiving First-Line Axitinib Plus Immuno-Oncology Agents for Advanced Renal Cell Carcinoma.
Semin Oncol Nurs
; 40(1): 151545, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38008655
7.
Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases.
Clin Cancer Res
; 24(17): 4081-4088, 2018 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29848570
8.
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
Eur J Cancer
; 94: 115-125, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29550566
9.
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
J Clin Oncol
; 35(6): 591-597, 2017 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28199818
10.
Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.
J Clin Oncol
; 32(18): 1889-94, 2014 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-24821883
11.
Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125].
Eur J Cancer
; 103: 287, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30270112